Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Dyne Therapeutics, Inc. Common Stock

DYN

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Last trade $16.07
Day change -$0.635 (-3.80%)
Day range $15.92 – $17.89
Volume 1,360,464
Market cap $3.13B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.13B
Price / earnings
—
Price / book
3.36×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.95×

Profitability

Earnings per share
-$3.23
Return on assets
-48.99%
Return on equity
-64.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.24×
Current ratio
12.99×
Quick ratio
12.99×
Cash ratio
10.09×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$568.76M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DYN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$35.33M$29.49M$24.39M$20.7M$16.67M$16.56M$15.93M$15.3M
Research and development$161.74M$152.17M$100.89M$95.43M$97.22M$99.24M$106.45M$81.81M
Total operating expenses$197.37M$181.66M$125.28M$116.13M$113.61M$115.79M$122.37M$97.11M
Operating income-$197.37M-$181.66M-$125.28M-$116.13M-$113.61M-$115.79M-$122.37M-$97.11M
Interest expense-$5.95M-$4.6M-$4.2M-$3.19M-$2.9M-$94K$0$0
Income before taxes-$193.55M-$178.56M-$120.85M-$111.96M-$108.04M-$110.86M-$115.36M-$89.54M
Income taxes$0$0$0$0$0$0$0$0
Net income-$193.55M-$178.56M-$120.85M-$111.96M-$108.04M-$110.86M-$115.36M-$89.54M
Net income attributable to common shareholders-$193.55M-$178.56M-$120.85M-$111.96M-$108.04M-$110.86M-$115.36M-$89.54M
EBITDA-$196.73M-$181.1M-$124.73M-$115.61M-$113.09M-$115.29M-$121.87M-$96.66M
Basic earnings per share-$1.06-$1.08-$0.73-$0.76-$0.76-$0.97-$1.05-$0.88
Diluted earnings per share-$1.06-$1.08-$0.73-$0.76-$0.76-$0.97-$1.05-$0.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, generating gross proceeds of approximately $375.2 million. The offering is expected to close on July 23, 2026, with underwriters granted a 30-day option to purchase an additional 2.745 million shares. Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers.

GlobeNewswire Inc.

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.

The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.

The Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

FCPM III Services B.V. reduced its Dyne Therapeutics position by 818,460 shares ($14.11 million) in May 2026, though the fund maintains Dyne as its second-largest holding at 11.8% of assets. Despite the partial exit, the stake reduction appears strategic rather than a loss of conviction, as Dyne shares have surged 56% over the past year. The company recently submitted a Biologics License Application for its lead Duchenne muscular dystrophy therapy z-rostudirsen, targeting potential FDA approval and U.S. launch in Q1 2027.

GlobeNewswire Inc.

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.